Relmada Therapeutics (RLMD) Retained Earnings (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Retained Earnings data on file, last reported at $935.9 million in Q1 2026.

• On a quarterly basis, Retained Earnings rose 37.47% year-over-year to $935.9 million in Q1 2026; TTM through Mar 2026 was $935.9 million, a 37.47% increase from a year earlier, with the FY2025 full-year figure at $784.7 million, up 222.44% from the prior year.
• Retained Earnings for Q1 2026 stood at $935.9 million, up from $784.7 million in the prior quarter.
• Over the last five years, Retained Earnings for RLMD reached as high as $935.9 million in Q1 2026 and fell as low as -$640.9 million in Q4 2024.
• Historically, Retained Earnings has averaged $195.9 million across 5 years, with a median of $602.5 million in 2022.
• Across the five-year window, Retained Earnings sank 217.82% in 2022 and soared 262.45% in 2023, its largest moves.
• Year by year, Retained Earnings stood at $602.5 million in 2022, then tumbled by 193.09% to -$560.9 million in 2023, then fell by 14.26% to -$640.9 million in 2024, then jumped by 222.44% to $784.7 million in 2025, then advanced by 19.27% to $935.9 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were $935.9 million in Q1 2026, $784.7 million in Q4 2025, and $687.8 million in Q3 2025.